Discounted Cash Flow (DCF) Analysis Levered
NovaBay Pharmaceuticals, Inc. (NBY)
$2.47
-0.08 (-3.14%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 18.23 | 12.51 | 6.60 | 9.93 | 8.42 | 7.51 | 6.70 | 5.97 | 5.32 | 4.75 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -6.27 | -5.57 | -7.93 | -4.72 | -9.19 | -5.34 | -4.76 | -4.25 | -3.79 | -3.38 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.24 | -0.04 | -0.02 | -0.03 | -0.05 | -0.04 | -0.04 | -0.03 | -0.03 | -0.03 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -6.51 | -5.61 | -7.95 | -4.75 | -9.24 | -5.39 | -4.80 | -4.28 | -3.82 | -3.40 |
Weighted Average Cost Of Capital
| Share price | $ 2.47 |
|---|---|
| Beta | 2.712 |
| Diluted Shares Outstanding | 0.62 |
| Cost of Debt | |
| Tax Rate | 0.00 |
| After-tax Cost of Debt | -% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 16.334 |
| Total Debt | 0.55 |
| Total Equity | 1.53 |
| Total Capital | 2.08 |
| Debt Weighting | 26.51 |
| Equity Weighting | 73.49 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 18.23 | 12.51 | 6.60 | 9.93 | 8.42 | 7.51 | 6.70 | 5.97 | 5.32 | 4.75 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -6.27 | -5.57 | -7.93 | -4.72 | -9.19 | -5.34 | -4.76 | -4.25 | -3.79 | -3.38 |
| Capital Expenditure | -0.24 | -0.04 | -0.02 | -0.03 | -0.05 | -0.04 | -0.04 | -0.03 | -0.03 | -0.03 |
| Free Cash Flow | -6.51 | -5.61 | -7.95 | -4.75 | -9.24 | -5.39 | -4.80 | -4.28 | -3.82 | -3.40 |
| WACC | ||||||||||
| PV LFCF | - | - | - | - | - | |||||
| SUM PV LFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | - |
| Free cash flow (t + 1) | -3.47 |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | -6.95 |
| Equity Value | - |
| Shares Outstanding | 0.62 |
| Equity Value Per Share | - |